BlackRock Health Sciences Term Trust
Sponsor: BlackRock · Inception Jan 29, 2020 · Pays monthly
Market priceShare price
$16.29
-1.09% ($-0.18)
NAVAsset value per share
—
as of —
Premium / discountPrice vs. assets
NAV unavailable
Close vs NAV, Oct 16, 2026
Distribution rate (price)Payout rate
8.10%
regular, annualised · on NAV —
Expense ratioAnnual cost
Not reported
no tagged fee table
LeverageBorrowing
Not reported
senior securities not tagged
Quote status: Market closed — last regular-session price · last trade Oct 16, 2026, 4:00 PM EDT (exchange time, ET) · retrieved Oct 16, 2026, 10:40 PM EDTRegular-session prices; extended-hours quotes are not displayed.
Full portfolio as filed on SEC Form N-PORT for the month ending Jun 30, 2026, filed Aug 25, 2026. 170 positions; weights are percent of net assets as reported. Weights sum to 100.0% — leverage, cash, derivatives and short positions mean totals need not equal 100%. This is a historical report, not a live portfolio.
Top 10 holdings
| # | Security | Type | Country | Weight | Value (USD) |
|---|---|---|---|---|---|
| 1 | Moderna Inc | Equity | United States | 3.56% | $38.5M |
| 2 | Johnson & Johnson | Equity | United States | 3.42% | $37M |
| 3 | Merck & Co Inc | Equity | United States | 3.00% | $32.4M |
| 4 | Biogen Inc | Equity | United States | 2.75% | $29.7M |
| 5 | PsiQuantum Corp | Equity | United States | 2.55% | $27.6M |
| 6 | Gilead Sciences Inc | Equity | United States | 2.51% | $27.1M |
| 7 | Edwards Lifesciences Corp | Equity | United States | 2.33% | $25.1M |
| 8 | Neurocrine Biosciences Inc | Equity | United States | 1.99% | $21.5M |
| 9 | Novartis AG | Equity | Switzerland | 1.98% | $21.4M |
| 10 | Amgen Inc | Equity | United States | 1.91% | $20.7M |
Asset class
| Asset class | % net assets | Value |
|---|---|---|
| Equity (common) | 95.27% | $1B |
| Short-term investment vehicle | 2.93% | $31.7M |
| Equity (preferred) | 1.76% | $19M |
| OTHER | 0.03% | $339K |
| Derivative (equity) | 0.00% | $4 |
Country (top 12)
| Country (top 12) | % net assets | Value |
|---|---|---|
| United States | 79.10% | $855M |
| Switzerland | 6.27% | $67.8M |
| United Kingdom | 4.73% | $51.2M |
| Denmark | 1.67% | $18M |
| Belgium | 1.24% | $13.4M |
| Germany | 1.24% | $13.4M |
| Netherlands | 1.02% | $11.1M |
| Japan | 0.85% | $9.2M |
| Ireland | 0.81% | $8.7M |
| Bermuda | 0.79% | $8.5M |
| Israel | 0.67% | $7.2M |
| Cayman Islands | 0.65% | $7M |
Region
| Region | % net assets | Value |
|---|---|---|
| United States | 79.10% | $855M |
| Developed Europe | 17.28% | $187M |
| Offshore domiciles | 1.50% | $16.2M |
| Japan | 0.85% | $9.2M |
| Middle East | 0.67% | $7.2M |
| Canada | 0.31% | $3.3M |
| Asia ex-Japan | 0.29% | $3.1M |
Issuer type
| Issuer type | % net assets | Value |
|---|---|---|
| Corporate | 98.45% | $1.1B |
| Registered fund | 1.55% | $16.8M |
| Other | 0.00% | $4 |
Fair-value level
| Fair-value level | % net assets | Value |
|---|---|---|
| Level 1 | 76.45% | $827M |
| Level 2 | 12.35% | $134M |
| Level 3 | 11.19% | $121M |
Level 3 = valued with unobservable inputs (typically private or illiquid).
Long / short
| Long / short | % net assets | Value |
|---|---|---|
| Long | 100.00% | $1.1B |
| N/A | 0.00% | $4 |
All allocation percentages use net assets as the denominator (N-PORT convention). A position's share of invested assets may differ from its share of the whole fund including cash and leverage.
All 170 positions
| Security | Identifier | Type | Issuer | Country | Balance | Units | Value (USD) | Weight | FV level |
|---|---|---|---|---|---|---|---|---|---|
| Moderna Inc | 60770K107 | Equity | CORP | United States | 549,814 | shares | $38.5M | 3.56% | 1 |
| Johnson & Johnson | 478160104 | Equity | CORP | United States | 145,639 | shares | $37M | 3.42% | 1 |
| Merck & Co Inc | 58933Y105 | Equity | CORP | United States | 252,501 | shares | $32.4M | 3.00% | 1 |
| Biogen Inc | 09062X103 | Equity | CORP | United States | 137,487 | shares | $29.7M | 2.75% | 1 |
| PsiQuantum Corprestricted | — | Equity | CORP | United States | 571,947 | shares | $27.6M | 2.55% | 3 |
| Gilead Sciences Inc | 375558103 | Equity | CORP | United States | 214,745 | shares | $27.1M | 2.51% | 1 |
| Edwards Lifesciences Corp | 28176E108 | Equity | CORP | United States | 277,879 | shares | $25.1M | 2.33% | 1 |
| Neurocrine Biosciences Inc | 64125C109 | Equity | CORP | United States | 127,517 | shares | $21.5M | 1.99% | 1 |
| Novartis AG | CH0012005267 | Equity | CORP | Switzerland | 136,779 | shares | $21.4M | 1.98% | 2 |
| Amgen Inc | 031162100 | Equity | CORP | United States | 57,154 | shares | $20.7M | 1.91% | 1 |
| Illumina Inc | 452327109 | Equity | CORP | United States | 116,338 | shares | $20.5M | 1.89% | 1 |
| Roche Holding AG | CH1499059983 | Equity | CORP | Switzerland | 46,443 | shares | $19.1M | 1.77% | 2 |
| Thermo Fisher Scientific Inc | 883556102 | Equity | CORP | United States | 34,802 | shares | $17.4M | 1.61% | 1 |
| AbbVie Inc | 00287Y109 | Equity | CORP | United States | 67,970 | shares | $17.1M | 1.58% | 1 |
| Genmab A/S | DK0010272202 | Equity | CORP | Denmark | 58,159 | shares | $15.9M | 1.47% | 2 |
| Axsome Therapeutics Inc | 05464T104 | Equity | CORP | United States | 62,902 | shares | $15.4M | 1.42% | 1 |
| Danaher Corp | 235851102 | Equity | CORP | United States | 79,322 | shares | $15.1M | 1.40% | 1 |
| Agilent Technologies Inc | 00846U101 | Equity | CORP | United States | 112,566 | shares | $15M | 1.38% | 1 |
| Natera Inc | 632307104 | Equity | CORP | United States | 52,122 | shares | $14.1M | 1.31% | 1 |
| BlackRock Liquidity Funds | 09248U718 | Short-term inv. | RF | United States | 13,962,826 | shares | $14M | 1.29% | 1 |
| Cytokinetics Inc | 23282W605 | Equity | CORP | United States | 162,568 | shares | $13.8M | 1.28% | 1 |
| Charles River Laboratories International Inc | 159864107 | Equity | CORP | United States | 60,883 | shares | $13.8M | 1.28% | 1 |
| UnitedHealth Group Inc | 91324P102 | Equity | CORP | United States | 32,974 | shares | $13.7M | 1.27% | 1 |
| GSK PLC | GB00BN7SWP63 | Equity | CORP | United Kingdom | 521,765 | shares | $13.7M | 1.27% | 2 |
| Guardant Health Inc | 40131M109 | Equity | CORP | United States | 89,770 | shares | $13.5M | 1.25% | 1 |
| UCB SA | BE0003739530 | Equity | CORP | Belgium | 44,287 | shares | $13.3M | 1.23% | 2 |
| Revolution Medicines Inc | 76155X100 | Equity | CORP | United States | 69,377 | shares | $13M | 1.20% | 1 |
| Sartorius AG | DE0007165631 | Preferred | CORP | Germany | 47,229 | shares | $12.4M | 1.15% | 2 |
| ADARX PHARMACEUTICALS INCrestricted | — | Equity | CORP | United States | 860,577 | shares | $12.2M | 1.13% | 3 |
| Bio-Techne Corp | 09073M104 | Equity | CORP | United States | 169,594 | shares | $12M | 1.11% | 1 |
| Dexcom Inc | 252131107 | Equity | CORP | United States | 173,259 | shares | $11.7M | 1.08% | 1 |
| Exelixis Inc | 30161Q104 | Equity | CORP | United States | 210,176 | shares | $11.4M | 1.06% | 1 |
| Immunocore Holdings PLC | 45258D105 | Equity | CORP | United Kingdom | 359,126 | shares | $11.4M | 1.05% | 1 |
| Rhythm Pharmaceuticals Inc | 76243J105 | Equity | CORP | United States | 101,573 | shares | $11.3M | 1.04% | 1 |
| Argenx SE | 04016X101 | Equity | CORP | Netherlands | 11,933 | shares | $11.1M | 1.02% | 1 |
| AstraZeneca PLC | GB0009895292 | Equity | CORP | United Kingdom | 57,869 | shares | $11M | 1.02% | 1 |
| Pfizer Inc | 717081103 | Equity | CORP | United States | 441,187 | shares | $10.6M | 0.98% | 1 |
| Vertex Pharmaceuticals Inc | 92532F100 | Equity | CORP | United States | 20,900 | shares | $10.4M | 0.96% | 1 |
| KARTOS THERAPEUTICS INCrestricted | — | Short-term inv. | CORP | United States | 2,364,954 | shares | $10.3M | 0.95% | 3 |
| Bristol-Myers Squibb Co | 110122108 | Equity | CORP | United States | 177,819 | shares | $10.2M | 0.95% | 1 |
| Boston Scientific Corp | 101137107 | Equity | CORP | United States | 239,074 | shares | $10.2M | 0.94% | 1 |
| GENESIS THERAPEUTICS INCrestricted | — | Equity | CORP | United States | 1,370,506 | shares | $10.1M | 0.94% | 3 |
| IQVIA Holdings Inc | 46266C105 | Equity | CORP | United States | 46,747 | shares | $9M | 0.84% | 1 |
| Alkermes PLC | IE00B56GVS15 | Equity | CORP | Ireland | 166,685 | shares | $8.7M | 0.81% | 1 |
| Cogent Biosciences Inc | 19240Q201 | Equity | CORP | United States | 221,514 | shares | $8.6M | 0.79% | 1 |
| Roivant Sciences Ltd | BMG762791017 | Equity | CORP | Bermuda | 240,456 | shares | $8.5M | 0.79% | 1 |
| Protagonist Therapeutics Inc | 74366E102 | Equity | CORP | United States | 68,855 | shares | $8.4M | 0.78% | 1 |
| Lonza Group AG | CH0013841017 | Equity | CORP | Switzerland | 12,000 | shares | $8.1M | 0.75% | 2 |
| LARONDE INCrestricted | — | Equity | CORP | United States | 482,077 | shares | $8M | 0.74% | 3 |
| NUMAB THERAPEUTICS AGrestricted | — | Equity | CORP | Switzerland | 1,139,305 | shares | $8M | 0.74% | 3 |
| Eisai Co Ltd | JP3160400002 | Equity | CORP | Japan | 304,900 | shares | $7.7M | 0.71% | 2 |
| Apogee Therapeutics Inc | 03770N101 | Equity | CORP | United States | 56,391 | shares | $7.5M | 0.69% | 1 |
| Intuitive Surgical Inc | 46120E602 | Equity | CORP | United States | 18,199 | shares | $7.2M | 0.67% | 1 |
| Teva Pharmaceutical Industries Ltd | 881624209 | Equity | CORP | Israel | 212,205 | shares | $7.2M | 0.67% | 1 |
| MBX Biosciences Inc | 55287L101 | Equity | CORP | United States | 128,549 | shares | $7.1M | 0.66% | 1 |
| LB Pharmaceuticals Inc | 50180M108 | Equity | CORP | United States | 207,987 | shares | $6.8M | 0.62% | 1 |
| Galderma Group AG | CH1335392721 | Equity | CORP | Switzerland | 29,482 | shares | $6.7M | 0.62% | 2 |
| INSITRO INCrestricted | — | Equity | CORP | United States | 999,296 | shares | $6.7M | 0.62% | 3 |
| Nuvalent Inc | 670703107 | Equity | CORP | United States | 52,024 | shares | $6.4M | 0.59% | 1 |
| Abbott Laboratories | 002824100 | Equity | CORP | United States | 68,889 | shares | $6.3M | 0.58% | 1 |
| Oruka Therapeutics Inc | 687604108 | Equity | CORP | United States | 65,030 | shares | $6.2M | 0.57% | 1 |
| Dianthus Therapeutics Inc | 252828108 | Equity | CORP | United States | 62,279 | shares | $6.1M | 0.56% | 1 |
| Arcus Biosciences Inc | 03969F109 | Equity | CORP | United States | 194,015 | shares | $6M | 0.55% | 1 |
| GSK PLC | 37733W204 | Equity | CORP | United Kingdom | 112,532 | shares | $5.9M | 0.55% | 1 |
| KAILERA THERAPEUTICS INCrestricted | — | Equity | CORP | United States | 250,286 | shares | $5.5M | 0.51% | 2 |
| EVERLY WELL INCrestricted | — | Equity | CORP | United States | 382,775 | shares | $5.4M | 0.50% | 3 |
| Lantheus Holdings Inc | 516544103 | Equity | CORP | United States | 48,294 | shares | $5.4M | 0.50% | 1 |
| NIKANG THERAPEUTICS INCrestricted | — | Equity | CORP | United States | 1,394,189 | shares | $5.3M | 0.49% | 3 |
| Waters Corp | 941848103 | Equity | CORP | United States | 14,015 | shares | $5.3M | 0.49% | 1 |
| Elanco Animal Health Inc | 28414H103 | Equity | CORP | United States | 210,509 | shares | $5.2M | 0.48% | 1 |
| Beam Therapeutics Inc | 07373V105 | Equity | CORP | United States | 150,763 | shares | $5.2M | 0.48% | 1 |
| Bio-Rad Laboratories Inc | 090572207 | Equity | CORP | United States | 17,608 | shares | $5.2M | 0.48% | 1 |
| Wuxi Biologics Cayman Inc | KYG970081173 | Equity | CORP | Cayman Islands | 1,152,500 | shares | $5.1M | 0.47% | 2 |
| Halozyme Therapeutics Inc | 40637H109 | Equity | CORP | United States | 63,226 | shares | $4.9M | 0.46% | 1 |
| Quanta Dialysis Technologies Ltdrestricted | — | Equity | CORP | United Kingdom | 115,766,240 | shares | $4.8M | 0.44% | 3 |
| Incyte Corp | 45337C102 | Equity | CORP | United States | 40,489 | shares | $4.6M | 0.42% | 1 |
| Alcon AG | CH0432492467 | Equity | CORP | Switzerland | 66,219 | shares | $4.4M | 0.41% | 1 |
| Stoke Therapeutics Inc | 86150R107 | Equity | CORP | United States | 132,656 | shares | $4.3M | 0.40% | 1 |
| MIRVIE INCrestricted | — | Preferred | CORP | United States | 2,793,833 | shares | $4.1M | 0.38% | 3 |
| Kiniksa Pharmaceuticals International Plc | GB00BRXB0C07 | Equity | CORP | United Kingdom | 64,037 | shares | $4.1M | 0.38% | 1 |
| ORNA THERAPEUTICS HOLDINGS LLCrestricted | — | Equity | CORP | United States | 3,584,906 | shares | $4.1M | 0.38% | 3 |
| Bruker Corp | 116794108 | Equity | CORP | United States | 64,684 | shares | $3.9M | 0.36% | 1 |
| Insmed Inc | 457669307 | Equity | CORP | United States | 36,385 | shares | $3.9M | 0.36% | 1 |
| Relay Therapeutics Inc | 75943R102 | Equity | CORP | United States | 183,230 | shares | $3.4M | 0.32% | 1 |
| Insulet Corp | 45784P101 | Equity | CORP | United States | 21,493 | shares | $3.3M | 0.30% | 1 |
| Palvella Therapeutics Inc | 697947109 | Equity | CORP | United States | 21,246 | shares | $3.2M | 0.30% | 1 |
| Intellia Therapeutics Inc | 45826J105 | Equity | CORP | United States | 190,477 | shares | $3.2M | 0.30% | 1 |
| Novocure Ltd | JE00BYSS4X48 | Equity | CORP | Jersey | 210,016 | shares | $3.2M | 0.29% | 1 |
| Viridian Therapeutics Inc | 92790C104 | Equity | CORP | United States | 173,120 | shares | $3.2M | 0.29% | 1 |
| Angitia Biopharmaceuticals Limitedrestricted | — | Short-term inv. | CORP | United States | 296,024 | shares | $2.9M | 0.27% | 3 |
| Erasca Inc | 29479A108 | Equity | CORP | United States | 159,240 | shares | $2.9M | 0.27% | 1 |
| RadNet Inc | 750491102 | Equity | CORP | United States | 46,906 | shares | $2.9M | 0.27% | 1 |
| Agios Pharmaceuticals Inc | 00847X104 | Equity | CORP | United States | 77,889 | shares | $2.9M | 0.27% | 1 |
| Alumis Inc | 022307102 | Equity | CORP | United States | 101,619 | shares | $2.9M | 0.26% | 1 |
| BlackRock Funds III | 066922519 | Short-term inv. | RF | United States | 2,803,531 | shares | $2.8M | 0.26% | 1 |
| PTC Therapeutics Inc | 69366J200 | Equity | CORP | United States | 34,361 | shares | $2.8M | 0.26% | 1 |
| Enliven Therapeutics Inc | 29337E102 | Equity | CORP | United States | 54,885 | shares | $2.8M | 0.26% | 1 |
| Bridgebio Pharma Inc | 10806X102 | Equity | CORP | United States | 36,695 | shares | $2.7M | 0.25% | 1 |
| Ionis Pharmaceuticals Inc | 462222100 | Equity | CORP | United States | 33,944 | shares | $2.7M | 0.25% | 1 |
| Metis TechBio Co Ltd | CNE100007LD1 | Equity | CORP | China | 1,300,500 | shares | $2.5M | 0.24% | 1 |
| NUCLEIX LTDrestricted | — | Preferred | CORP | United States | 2,380,780 | shares | $2.5M | 0.23% | 3 |
| BRIGHT PEAK THERAPEUTICS INCrestricted | — | Equity | CORP | United States | 3,191,830 | shares | $2.4M | 0.22% | 3 |
| Sagimet Biosciences Inc | 786700104 | Equity | CORP | United States | 301,060 | shares | $2.3M | 0.22% | 1 |
| Bright Minds Biosciences Inc | 10919W405 | Equity | CORP | Canada | 31,933 | shares | $2.2M | 0.21% | 1 |
| Zealand Pharma A/S | DK0060257814 | Equity | CORP | Denmark | 46,920 | shares | $2.1M | 0.19% | 2 |
| BridgeBio Oncology Therapeutics Inc | 107924102 | Equity | CORP | United States | 263,669 | shares | $2M | 0.19% | 1 |
| Denali Therapeutics Inc | 24823R105 | Equity | CORP | United States | 78,053 | shares | $2M | 0.19% | 1 |
| Avalo Therapeutics Inc | 05338F306 | Equity | CORP | United States | 108,171 | shares | $2M | 0.18% | 1 |
| Vaxcyte Inc | 92243G108 | Equity | CORP | United States | 33,589 | shares | $2M | 0.18% | 1 |
| Tango Therapeutics Inc | 87583X109 | Equity | CORP | United States | 62,293 | shares | $1.9M | 0.18% | 1 |
| Aktis Oncology Inc | 01021M104 | Equity | CORP | United States | 58,563 | shares | $1.9M | 0.17% | 1 |
| BioMarin Pharmaceutical Inc | 09061G101 | Equity | CORP | United States | 31,662 | shares | $1.8M | 0.17% | 1 |
| Dyne Therapeutics Inc | 26818M108 | Equity | CORP | United States | 80,931 | shares | $1.8M | 0.17% | 1 |
| Monte Rosa Therapeutics Inc | 61225M102 | Equity | CORP | United States | 70,406 | shares | $1.7M | 0.16% | 1 |
| Glaukos Corp | 377322102 | Equity | CORP | United States | 12,098 | shares | $1.7M | 0.16% | 1 |
| United Therapeutics Corp | 91307C102 | Equity | CORP | United States | 3,080 | shares | $1.7M | 0.15% | 1 |
| Scholar Rock Holding Corp | 80706P103 | Equity | CORP | United States | 30,077 | shares | $1.7M | 0.15% | 1 |
| MIRVIE SERIES C | — | Short-term inv. | CORP | United States | 724,806 | shares | $1.6M | 0.15% | 3 |
| Nuvation Bio Inc | 67080N101 | Equity | CORP | United States | 283,833 | shares | $1.6M | 0.15% | 1 |
| Kymera Therapeutics Inc | 501575104 | Equity | CORP | United States | 13,937 | shares | $1.6M | 0.15% | 1 |
| Eikon Therapeutics Inc | 282564103 | Equity | CORP | United States | 121,628 | shares | $1.6M | 0.15% | 1 |
| Bicara Therapeutics Inc | 055477103 | Equity | CORP | United States | 52,958 | shares | $1.6M | 0.15% | 1 |
| Immunome Inc | 45257U108 | Equity | CORP | United States | 71,450 | shares | $1.5M | 0.14% | 1 |
| Daiichi Sankyo Co Ltd | JP3475350009 | Equity | CORP | Japan | 93,900 | shares | $1.5M | 0.14% | 2 |
| Ultragenyx Pharmaceutical Inc | 90400D108 | Equity | CORP | United States | 43,975 | shares | $1.5M | 0.14% | 1 |
| CELLARITY INCrestricted | — | Equity | CORP | United States | 2,430,833 | shares | $1.4M | 0.13% | 3 |
| Maze Therapeutics Inc | 578784100 | Equity | CORP | United States | 44,725 | shares | $1.3M | 0.12% | 1 |
| Kailera Therapeutics Inc | 482931102 | Equity | CORP | United States | 52,563 | shares | $1.2M | 0.11% | 1 |
| Neurogene Inc | 64135M105 | Equity | CORP | United States | 36,199 | shares | $1.1M | 0.11% | 1 |
| Definium Therapeutics Inc | 24477V105 | Equity | CORP | Canada | 23,198 | shares | $1.1M | 0.10% | 1 |
| EyePoint Inc | 30233G209 | Equity | CORP | United States | 75,092 | shares | $1.1M | 0.10% | 1 |
| ORIC Pharmaceuticals Inc | 68622P109 | Equity | CORP | United States | 99,005 | shares | $1.1M | 0.10% | 1 |
| Akeso Inc | KYG0146B1032 | Equity | CORP | Cayman Islands | 95,000 | shares | $1.1M | 0.10% | 2 |
| BioNTech SE | 09075V102 | Equity | CORP | Germany | 11,340 | shares | $1.1M | 0.10% | 1 |
| GOLDFINCH BIO INCrestricted | — | Equity | CORP | United States | 3,409,215 | shares | $1M | 0.09% | 3 |
| Enanta Pharmaceuticals Inc | 29251M106 | Equity | CORP | United States | 69,729 | shares | $1M | 0.09% | 1 |
| REGENXBIO Inc | 75901B107 | Equity | CORP | United States | 81,282 | shares | $974K | 0.09% | 1 |
| Summit Therapeutics Inc | 86627T108 | Equity | CORP | United States | 63,310 | shares | $922K | 0.09% | 1 |
| MoonLake Immunotherapeutics | 61559X104 | Equity | CORP | Cayman Islands | 43,395 | shares | $845K | 0.08% | 1 |
| Kodiak Sciences Inc | 50015M109 | Equity | CORP | United States | 21,542 | shares | $839K | 0.08% | 1 |
| CytomX Therapeutics Inc | 23284F105 | Equity | CORP | United States | 215,748 | shares | $809K | 0.07% | 1 |
| Vor BioPharma Inc | 929033207 | Equity | CORP | United States | 43,710 | shares | $805K | 0.07% | 1 |
| EXO IMAGING INCrestricted | — | Equity | CORP | United States | 1,076,504 | shares | $788K | 0.07% | 3 |
| Arvinas Inc | 04335A105 | Equity | CORP | United States | 94,854 | shares | $788K | 0.07% | 1 |
| MapLight Therapeutics Inc | 56565P103 | Equity | CORP | United States | 21,112 | shares | $757K | 0.07% | 1 |
| Ocular Therapeutix Inc | 67576A100 | Equity | CORP | United States | 76,913 | shares | $755K | 0.07% | 1 |
| Allogene Therapeutics Inc | 019770106 | Equity | CORP | United States | 344,966 | shares | $718K | 0.07% | 1 |
| Biohaven Ltd | VGG1110E1079 | Equity | CORP | British Virgin Islands | 46,808 | shares | $697K | 0.06% | 1 |
| AFFINIVAX INCrestricted | — | Equity | CORP | United States | 183,164 | shares | $670K | 0.06% | 3 |
| WaVe Life Sciences Ltd | SG9999014716 | Equity | CORP | Singapore | 96,283 | shares | $559K | 0.05% | 1 |
| 4D Molecular Therapeutics Inc | 35104E100 | Equity | CORP | United States | 41,862 | shares | $557K | 0.05% | 1 |
| Syndax Pharmaceuticals Inc | 87164F105 | Equity | CORP | United States | 24,320 | shares | $532K | 0.05% | 1 |
| TScan Therapeutics Inc | 89854M101 | Equity | CORP | United States | 405,905 | shares | $398K | 0.04% | 1 |
| Upstream Bio Inc | 91678A107 | Equity | CORP | United States | 56,530 | shares | $391K | 0.04% | 1 |
| Corvus Pharmaceuticals Inc | 221015100 | Equity | CORP | United States | 24,771 | shares | $370K | 0.03% | 1 |
| ABCURO SERIES B | — | Equity | CORP | United Kingdom | 1,092,954 | shares | $339K | 0.03% | 3 |
| Nyxoah SA | BE0974358906 | Equity | CORP | Belgium | 112,019 | shares | $189K | 0.02% | 1 |
| Annexon Inc | 03589W102 | Equity | CORP | United States | 32,267 | shares | $184K | 0.02% | 1 |
| AMUNIX INCrestricted | — | Equity | CORP | United States | 5,657,068 | shares | $170K | 0.02% | 3 |
| CONTRA ABIOMED INC | 003CVR016 | OTHER | CORP | United States | 98,636 | shares | $150K | 0.01% | 3 |
| CONTRA MIRATI THERAPEU | 604CVR027 | OTHER | CORP | United States | 180,175 | shares | $142K | 0.01% | 3 |
| ABCURO SERIES C EQUITY | — | Short-term inv. | CORP | United States | 241,900 | shares | $79.8K | 0.01% | 3 |
| CONTRA BLUEPRINT MEDIC | 096CVR048 | OTHER | CORP | United States | 36,582 | shares | $36.2K | 0.00% | 3 |
| Gossamer Bio Inc | 38341P102 | Equity | CORP | United States | 60,195 | shares | $9.9K | 0.00% | 1 |
| CONTRA VIGIL NEUROSCIE | 926CVR010 | OTHER | CORP | United States | 131,344 | shares | $6.6K | 0.00% | 3 |
| SWIFT HEALTH SYSTEMS INCrestricted | — | Equity | CORP | United States | 2,078 | shares | $4.6K | 0.00% | 3 |
| CONTRA ARCELLX INC | 039CVR014 | OTHER | CORP | United States | 31,135 | shares | $2.2K | 0.00% | 2 |
| CONTRA HOLOGIC INCORPO | 436CVR021 | OTHER | CORP | United States | 137,197 | shares | $1.4K | 0.00% | 2 |
| GOLDFINCH EQUITY WARRANTS | — | Equity deriv. | OTHER | United States | 441,503 | shares | $4 | 0.00% | 3 |
| CONTRA FREQUENCY THERA | 358CVR025 | OTHER | CORP | United States | 231,775 | shares | $2 | 0.00% | 3 |
Equities show share counts; bonds and loans show principal amount. Coupon, maturity and ratings are shown where the filing discloses them. Source: SEC N-PORT via market-data vendor re-serve, position-level.
Holdings reports on file
| Report date | Filed | Positions | Σ weight | Net assets (calc.) | Coverage |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 25, 2026 | 170 | 100.0% | $1.1B | full |
| Mar 31, 2026 | May 28, 2026 | 171 | 100.0% | $1B | full |
| Dec 31, 2025 | Feb 24, 2026 | 170 | 100.0% | $1.1B | full |
Net assets here are calculated from position values ÷ reported weights (median across positions), not a reported figure.
CEF Explorer research page for BlackRock Health Sciences Term Trust. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.